Moore D - Search Results

1

A Phase II Study of Long-Acting Octreotide in Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher.

Shah U, O'Neil B, Allen J, Goldberg RM, Bernard S, Moore D, Venook AP, Morse MM. Shah U, et al. Among authors: moore d. Gastrointest Cancer Res. 2009 Mar;3(2):45-8. Gastrointest Cancer Res. 2009. PMID: 19461906 Free PMC article.

2

High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.

O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM. O'Neil BH, et al. Among authors: moore dt. J Clin Oncol. 2007 Aug 20;25(24):3644-8. doi: 10.1200/JCO.2007.11.7812. J Clin Oncol. 2007. PMID: 17704414

3

Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.

Stinchcombe TE, Socinski MA, Lee CB, Hayes DN, Moore DT, Goldberg RM, Dees EC. Stinchcombe TE, et al. Among authors: moore dt. J Thorac Oncol. 2008 May;3(5):521-6. doi: 10.1097/JTO.0b013e31816de2a7. J Thorac Oncol. 2008. PMID: 18449006 Free PMC article. Clinical Trial.

4

Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.

Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH. Tsai AL, et al. Among authors: moore dt. J Vasc Interv Radiol. 2010 Sep;21(9):1377-84. doi: 10.1016/j.jvir.2010.04.027. Epub 2010 Aug 5. J Vasc Interv Radiol. 2010. PMID: 20691606 Free PMC article.

5

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. O'Neil BH, et al. J Clin Oncol. 2011 Jun 10;29(17):2350-6. doi: 10.1200/JCO.2010.33.9432. Epub 2011 Apr 25. J Clin Oncol. 2011. PMID: 21519015 Free PMC article. Clinical Trial.

6

Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma.

Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Sanoff HK, et al. Gastrointest Cancer Res. 2011 May;4(3):78-83. Gastrointest Cancer Res. 2011. PMID: 22043322 Free PMC article.

7

Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma.

Morse MA, Hanks BA, Suhocki P, Doan PL, Liu EA, Frost P, Bernard SA, Tsai A, Moore DT, O'Neil BH. Morse MA, et al. Clin Colorectal Cancer. 2012 Sep;11(3):185-90. doi: 10.1016/j.clcc.2011.11.003. Epub 2012 Jan 26. Clin Colorectal Cancer. 2012. PMID: 22280845

8

Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.

Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, Fernando NH, McCaffrey J, El-Rayes BF, Horgan AM, Sherrill GB, Yacoub GH, O'Neil BH. Sanoff HK, et al. Among authors: moore dt. Cancer. 2018 Aug 1;124(15):3118-3126. doi: 10.1002/cncr.31552. Epub 2018 Jun 15. Cancer. 2018. PMID: 29905927 Free article. Clinical Trial.

9

Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.

Sanoff HK, Moon DH, Moore DT, Boles J, Bui C, Blackstock W, O'Neil BH, Subramaniam S, McRee AJ, Carlson C, Lee MS, Tepper JE, Wang AZ. Sanoff HK, et al. Nanomedicine. 2019 Jun;18:189-195. doi: 10.1016/j.nano.2019.02.021. Epub 2019 Mar 8. Nanomedicine. 2019. PMID: 30858085 Free PMC article. Clinical Trial.

10

Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.

Liu Y, Lyu J, Bell Burdett K, Sibley AB, Hatch AJ, Starr MD, Brady JC, Hammond K, Marmorino F, Rossini D, Goldberg RM, Falcone A, Cremolini C, Owzar K, Ivanova A, Moore DT, Lee MS, Sanoff HK, Innocenti F, Nixon AB. Liu Y, et al. Among authors: moore dt. Mol Cancer Ther. 2020 Oct;19(10):2146-2154. doi: 10.1158/1535-7163.MCT-20-0249. Epub 2020 Aug 3. Mol Cancer Ther. 2020. PMID: 32747417

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,115 results

Search Page

Filters